<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202605</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-203</org_study_id>
    <nct_id>NCT00202605</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SPD465 in Adults With ADHD</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate how safe and how well SPD465 works compared to&#xD;
      placebo in adults with ADHD. It is hypothesized that SPD465 will achieve an extended duration&#xD;
      of clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2005</start_date>
  <completion_date type="Actual">January 6, 2006</completion_date>
  <primary_completion_date type="Actual">January 6, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>0.5 hours pre-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>2 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>4 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>8 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>12 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>14 hours post-dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PERMP (Permanent Product Measure of Performance)</measure>
    <time_frame>16 hours post-dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Segment Rating System (ADHD-RS[TSRS])</measure>
    <time_frame>5½, 11, and 16½ hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject self report (ADHD-SRS) of ADHD</measure>
    <time_frame>approximately 5½, 11, and 16½ hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Throughout the study period of approximately 3.25 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Study orientation and randomization visit, Week 1 after Study orientation and randomization visit, Week 2 after Study orientation and randomization visit</time_frame>
  </secondary_outcome>
  <enrollment>72</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary diagnosis of ADHD using DSM-IV-TR criteria (at least 6 of the 9 subtype&#xD;
             criteria met)&#xD;
&#xD;
          -  Baseline ADHD-RS-IV score =&gt;24&#xD;
&#xD;
          -  IQ score of =&gt; 80 (using Kaufman Brief Intelligence Test)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &lt; 18.5 or &gt; 30 kg/m2&#xD;
&#xD;
          -  Diagnosis of Post Traumatic Stress Disorder, psychosis, bipolar illness, severe&#xD;
             obsessive compulsive disorder, severe depressive or severe anxiety disorder&#xD;
&#xD;
          -  History of seizure disorder or a lifetime history of any seizures (other than&#xD;
             infantile febrile seizures), any tic disorder, or a current diagnosis and/or family&#xD;
             history of Tourette's Disorder&#xD;
&#xD;
          -  History of uncontrolled hypertension or currently hypertensive&#xD;
&#xD;
          -  Subjects who have taken atomoxetine (STRATTERA) within 30 days prior to screening&#xD;
&#xD;
          -  Current (or history within the last 12 months) of drug dependence or substance abuse&#xD;
             disorder according to DSM-IV-TR criteria (excluding nicotine)&#xD;
&#xD;
          -  Female subject is pregnant or lactating, less than 3 months post partum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Study Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Child Development Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayou City Research, Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

